Expertise in
8
conditions

Dr. Aravindhan Veerapandiyan

Pediatric Neurology
Arkansas Children's Hospital
1 Childrens Way, 
Little Rock, AR 
Accepting New Patients
Expertise in
8
conditions
Arkansas Children's Hospital
1 Childrens Way, 
Little Rock, AR 

Overview

Aravindhan Veerapandiyan is a Pediatric Neurologist practicing medicine in Little Rock, Arkansas.

Dr. Veerapandiyan is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, and Gastrostomy.

He is actively involved in clinical research, co-authoring 75 peer reviewed articles and participating in 8 clinical trials. Dr. Veerapandiyan is currently accepting new patients.

Specialties

Pediatric Neurology

Licenses

Neurology with Special Qualifications in Neurology in AR

Languages Spoken

English
Tamil

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
HMO Partners
  • POS
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 14 Less Insurance Carriers -

Locations

Arkansas Children's Hospital
1 Childrens Way, Little Rock, AR 72202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Terminated
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Biological
Study Drug: CAP-1002
Study Phase: Phase 3
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Terminated
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), Type 2C (LGMD2C/R5), and Type 2A (LGMD2A/R1)
Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), Type 2C (LGMD2C/R5), and Type 2A (LGMD2A/R1)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
View 7 Less Clinical Trials

75 Total Publications

Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD.
Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD.
Journal: Journal of comparative effectiveness research
Published: April 10, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Kenneth R. Habetz
Pediatric Neurology
Expertise in
17
conditions
Dr. Kenneth R. Habetz
Pediatric Neurology
Referral may be required

Arkansas Children's Hospital

1 Childrens Way, 
Little Rock, AR 
 (0.1 miles away)
501-364-1850
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kenneth Habetz is a Pediatric Neurologist practicing medicine in Little Rock, Arkansas. Dr. Habetz is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Genetic Epilepsy with Febrile Seizures Plus (GEFS+), Benign Rolandic Epilepsy, Seizures, and Absence Seizure. Dr. Habetz is currently accepting new patients.

Expertise in
0
conditions
Dr. Sarah B. Cobb
Pediatric Neurology
Expertise in
0
conditions
Dr. Sarah B. Cobb
Pediatric Neurology
Referral may be required

Arkansas Children's Hospital

1 Childrens Way, 
Little Rock, AR 
 (0.1 miles away)
501-364-1850
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sarah Cobb is a Pediatric Neurologist practicing medicine in Little Rock, Arkansas. Her clinical expertise encompasses West Syndrome, Spasmus Nutans, Rasmussen Encephalitis, and Seizures. Dr. Cobb is currently accepting new patients.

Expertise in
0
conditions
Dr. Gregory B. Sharp
Pediatric Neurology
Expertise in
0
conditions
Dr. Gregory B. Sharp
Pediatric Neurology
Referral may be required

Arkansas Children's Hospital

1 Childrens Way, 
Little Rock, AR 
 (0.1 miles away)
501-364-1850
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gregory Sharp is a Pediatric Neurologist practicing medicine in Little Rock, Arkansas. His clinical expertise encompasses West Syndrome, Spasmus Nutans, Epilepsy, and Neurofibromatosis Type 1 (NF1). Dr. Sharp is currently accepting new patients.

Frequently Asked Questions about Dr. Aravindhan Veerapandiyan

How do I make an appointment with Dr. Aravindhan Veerapandiyan?

You can book an appointment with Dr. Aravindhan Veerapandiyan by calling their office at 501-364-1850. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aravindhan Veerapandiyan a top-rated expert for Becker Muscular Dystrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aravindhan Veerapandiyan is classified as an Elite expert for Becker Muscular Dystrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aravindhan Veerapandiyan specialize in?

While Dr. Aravindhan Veerapandiyan is a Pediatric Neurology, they have specific expertise in Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Spinal Muscular Atrophy (SMA). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Neurology.

Does Dr. Aravindhan Veerapandiyan participate in research or clinical trials?

Yes. Dr. Aravindhan Veerapandiyan has published 75 articles and abstracts on conditions like Becker Muscular Dystrophy. You can view a list of Dr. Aravindhan Veerapandiyan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aravindhan Veerapandiyan accept my insurance?

Dr. Aravindhan Veerapandiyan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 501-364-1850 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Veerapandiyan's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile